National Cancer Institute CRO Aviano

Mechanisms of p53 inactivation in TP53 wild type tumors and factors affecting sensitivity to MDM2 inhibitors

Posted by National Cancer Institute CRO AvianoResponsive · Knowhow and Research output · Italy

Summary of the technology

The research group led by Dr Roberta Maestro demonstrated that the overexpression of the protein Twist, detectable in a large fraction of sarcomas but also in a fraction of carcinomas, facilitates the MDM2-mediated degradation of p53 by making p53 more susceptible to MDM2 attack.

The p53:MDM2 interplay is the target of a number of compounds currently under clinical trials. These compounds (MDM2i) are aimed at alleviating p53 from MDM2-mediated degradation and hence at restoring the p53 tumor suppressive activity.

Maestro and coworkers gathered data indicating that the expression of Twist may significantly impact on the activity of these drugs.

Description of the technology

Twist gain-of-function and loss-of-function cell models:

• to explore p53 inactivation mechanisms in TP53 wild type tumors
• to evaluate activity of p53:MDM2 inhibitors (MDM2i)
• to study MDM2i resistance mechanisms

What we offer:

• Deep knowledge on p53 inactivation mechanisms in TP53 wild type tumors
• Solid knowhow on the generation of gain/loss-of-function cell models

Technology Owner

National Cancer Institute CRO Aviano

Research Institute

Additional information (attached documents)

Related keywords

  • Biological Sciences
  • Medicine, Human Health
  • Cytology, Cancerology, Oncology
  • Pharmaceutical Products / Drugs
  • Prototypes, trials and pilot schemes
  • Clinical Research, Trials
  • Medical Health related

About National Cancer Institute CRO Aviano

Research Institute from Italy

National Cancer Institute CRO-Aviano is an Italian public institute funded in 1984 and is committed to pursue excellence in all aspects of clinical oncology and management of health services. CRO is also an excellence in translational and clinical research activity. Our structure performs an average of 378740 patient exams/year, 8295 pts admitted/year (50% are extra-regional) for medium-long term stays and day hospital treatment. Scientific production sets above of 230 scientific papers in journals with Impact Factor (IF), ranking in the set of the 10% most cited papers in their respective scientific field, having a total IF>1000. Clinical trials average 60 per year.

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.